Pulmonary Antihypertensive Agents - Prostacyclin-type

Pulmonary antihypertensive agents of the prostacyclin type—commonly categorized in professional pharmacotherapy as prostacyclin pathway agents, prostacyclin analogs, or prostacyclin receptor agonists—are synthetic or non-prostanoid medications designed to mimic endogenous prostacyclin These agents primarily bind to prostacyclin (IP) receptors on vascular smooth muscle, stimulating intracellular cyclic AMP production to induce potent pulmonary vasodilation, inhibit smooth muscle cell proliferatio...

Pulmonary antihypertensive agents of the prostacyclin type—commonly categorized in professional pharmacotherapy as prostacyclin pathway agents, prostacyclin analogs, or prostacyclin receptor agonists—are synthetic or non-prostanoid medications designed to mimic endogenous prostacyclin These agents primarily bind to prostacyclin (IP) receptors on vascular smooth muscle, stimulating intracellular cyclic AMP production to induce potent pulmonary vasodilation, inhibit smooth muscle cell proliferatio...

These agents primarily bind to prostacyclin (IP) receptors on vascular smooth muscle, stimulating intracellular cyclic AMP production to induce potent pulmonary vasodilation, inhibit smooth muscle cell proliferation, and decrease platelet aggregation

Therapeutically, this drug class is indicated for the treatment of World Health Organization Group 1 pulmonary arterial hypertension and select forms of pulmonary hypertension associated with interstitial lung disease, where it functions to reduce pulmonary vascular resistance, improve exercise tolerance, and delay clinical disease progression

Therapeutically, this drug class is indicated for the treatment of World Health Organization Group 1 pulmonary arterial hypertension and select forms of pulmonary hypertension associated with interstitial lung disease, where it functions to reduce pulmonary vascular resistance, improve exercise tolerance, and delay clinical disease progression